Clinical trial
A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis
NCT03945279 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis
- Lead sponsor
- Biogen
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 30, 2019
- Completion date
- June 21, 2021
- Enrollment
- 49 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.